The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians

Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy

(2013) Julie Doan et al.   ANNALS OF PHARMACOTHERAPY

Ageing in general practice (AGP) trial: a cluster randomised trial to examine the effectiveness of peer education on GP diagnostic assessment and management of dementia

(2012) Constance D Pond et al.   BMC Family Practice

Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population

(2012) Ameet Bakhai et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Detection and Prevention of Drug–Drug Interactions in the Hospitalized Elderly: Utility of New Cytochrome P450–Based Software

(2011) Hubert Zakrzewski-Jakubiak et al.   American Journal Geriatric Pharmacotherapy

Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment

(2011) Thomas M. Polasek et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence of potentially hazardous drug interactions amongst Australian veterans

(2010) Elizabeth E. Roughead et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids

(2010) Joseph V. Pergolizzi Jr. et al.   Pain Practice

Incidence of fatal adverse drug reactions: a population based study

(2008) Karin Wester et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4

(2008) Shu-Feng Zhou   CURRENT DRUG METABOLISM

Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases

(2008) Eileen E. Ming et al.   Journal of Clinical Lipidology